BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16613764)

  • 21. Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted reference value.
    Gutiérrez A; Martínez-Serra J; Barceló B; Sampol A; Viñas L; González G; Bea MD; Amat JC; Martín J; Ramos R; Bautista A; Forteza-Rey J; Rodríguez J; Besalduch J
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):582-9. PubMed ID: 20201996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma.
    Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Michallet AS; Warzocha K; Biliński P; Boyle P; Coiffier B; Salles G
    Arch Immunol Ther Exp (Warsz); 2013 Apr; 61(2):165-74. PubMed ID: 23283519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
    Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Plasma interleukin-6 and interleukin-10 levels in different subtypes of lymphoma and their clinical significance].
    Wang X; Zhao HR; Gu X; Liu P; Bikmituofu H
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Aug; 31(8):1360-4. PubMed ID: 21868324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary thyroid lymphoma: case series with literature review.
    Kebapcilar L; Alacacioglu I; Comlekci A; Ozcan MA; Piskin O; Kargi A; Undar B; Yesil S
    J BUON; 2009; 14(2):295-9. PubMed ID: 19650181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
    Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis.
    Ballonoff A; Rusthoven KE; Schwer A; McCammon R; Kavanagh B; Bassetti M; Newman F; Rabinovitch R
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1465-71. PubMed ID: 18495371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors in primary gastric lymphoma.
    Medina-Franco H; Germes SS; Maldonado CL
    Ann Surg Oncol; 2007 Aug; 14(8):2239-45. PubMed ID: 17546474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
    Sohn BS; Park I; Kim EK; Yoon DH; Lee SS; Kang BW; Jang G; Choi YH; Kim C; Lee DH; Kim S; Huh J; Suh C
    Bone Marrow Transplant; 2009 Sep; 44(5):287-93. PubMed ID: 19234508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.
    Rueda A; Sabin P; Rifá J; Llanos M; Gómez-Codina J; Lobo F; García R; Herrero J; Provencio M; Jara C;
    Hematol Oncol; 2008 Mar; 26(1):27-32. PubMed ID: 17868190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
    J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
    Hsia CY; Huo TI; Chiang SY; Lu MF; Sun CL; Wu JC; Lee PC; Chi CW; Lui WY; Lee SD
    Eur J Surg Oncol; 2007 Mar; 33(2):208-12. PubMed ID: 17140760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
    Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS
    Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
    Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
    Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
    Gundrum JD; Mathiason MA; Moore DB; Go RS
    J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.
    Dlouhy I; Filella X; Rovira J; Magnano L; Rivas-Delgado A; Baumann T; Martínez-Trillos A; Balagué O; Martínez A; González-Farre B; Karube K; Gine E; Delgado J; Campo E; López-Guillermo A
    Leuk Res; 2017 Aug; 59():20-25. PubMed ID: 28544905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients.
    Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Shono Y; Morioka M; Kawamura T; Masauzi N; Kakinoki Y; Kobayashi H; Kunieda Y; Kasai M; Kurosawa M; Asaka M; Imamura M
    Eur J Haematol; 2006 Nov; 77(5):403-9. PubMed ID: 16930137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.